A1C and Blood Sugar: Understanding the ADAG Formula and ADA 2024 Thresholds

Haemoglobin A1C (HbA1c), commonly called A1C, is a blood test that reflects your average blood glucose over approximately the past three months. When glucose circulates in the bloodstream, it binds irreversibly to haemoglobin inside red blood cells — a process called glycation. Since red blood cells live roughly 90 days, the percentage of glycated haemoglobin (the A1C value) provides a reliable snapshot of long-term glucose control without the day-to-day variability of fingerstick readings.

The ADAG Formula: From A1C to Average Blood Sugar

In 2008, Nathan DM and colleagues published the A1C-Derived Average Glucose (ADAG) study in Diabetes Care (PMID 18540046). Using continuous glucose monitors plus 7-point capillary profiles in 507 participants across 10 countries, they derived the following linear equation: eAG (mg/dL) = 28.7 × A1C% − 46.7. The reverse is: A1C% = (eAG + 46.7) / 28.7. The American Diabetes Association (ADA) now recommends that laboratories report eAG alongside A1C values, because mg/dL and mmol/L are the familiar units patients see on home glucose meters.

HbA1c vs Fasting Glucose vs OGTT — When Each Is Preferred

The ADA 2024 Standards of Care (Diabetes Care 47 Suppl 1) accept three equivalent tests for diagnosing diabetes: HbA1c ≥ 6.5%, fasting plasma glucose (FPG) ≥ 126 mg/dL after 8-hour fast, or 2-hour plasma glucose ≥ 200 mg/dL during a 75 g oral glucose tolerance test (OGTT). Each captures a different physiology and the three tests do not always agree in the same patient.

ADA 2024 Classification: Normal, Prediabetes, Diabetes

The ADA Standards of Medical Care in Diabetes — 2024 defines three categories based on A1C. Diagnosis requires two abnormal results (either two A1C ≥ 6.5%, or one A1C and one FPG/OGTT) on separate days unless unequivocal hyperglycemic symptoms with random glucose ≥ 200 mg/dL are present.

A1C Targets for People with Diabetes

For most non-pregnant adults with diabetes, ADA 2024 recommends an A1C target of less than 7.0% (eAG < 154 mg/dL) to reduce microvascular complications (retinopathy, nephropathy, neuropathy). Targets may be individualised: less than 6.5% is reasonable for patients with short diabetes duration, long life expectancy, and no significant cardiovascular disease (if achievable without hypoglycaemia). A target of less than 8.0% is acceptable for older adults, those with hypoglycaemia unawareness, limited life expectancy, or complex comorbidities.

Time in Range (CGM) vs HbA1c

A1C reflects average glucose but misses glucose variability. Two patients can share the same A1C while one has frequent hypoglycaemia compensated by hyperglycaemia peaks. The 2019 International Consensus on Time in Range (Battelino T et al., Diabetes Care, PMID 31177185) defined Time in Range (TIR) as the percentage of glucose readings between 70–180 mg/dL captured by continuous glucose monitors (CGM). The consensus target for most adults with type 1 or type 2 diabetes is TIR > 70%, with time below 70 mg/dL < 4% and time below 54 mg/dL < 1%.

Beck RW et al. 2019 (Diabetes Care, PMID 30352896) validated TIR as a clinically meaningful endpoint: each 10-percentage-point lower TIR was associated with a 64% increase in retinopathy progression and 40% increase in microalbuminuria development. As a rule of thumb, a 10% rise in TIR corresponds to ~0.5–0.8% drop in A1C — but TIR captures hypoglycemia exposure that A1C cannot show, which is why ADA 2024 now recommends reporting both whenever CGM is available.

Why HbA1c Can Be Misleading

A1C is not reliable when red blood cell turnover or haemoglobin structure are abnormal. Conditions that falsely LOWER A1C (red cells live shorter than 90 days): haemolytic anaemia, recent blood transfusion or large bleed, sickle cell disease, beta-thalassemia, advanced chronic kidney disease on erythropoietin, second/third-trimester pregnancy. Conditions that falsely RAISE A1C: iron-deficiency anaemia, vitamin B12/folate deficiency, splenectomy. Some hemoglobin variants (HbS, HbC, HbE) can also produce method-dependent artifacts depending on the assay used.

When A1C is unreliable, alternatives include fructosamine (2–3 week average), glycated albumin (2–4 week average), or continuous glucose monitoring with a Glucose Management Indicator (GMI) reported in A1C-equivalent units. Ethnicity-related differences in glycation rate have also been documented; A1C may be 0.1–0.4% higher in Black, Hispanic and Asian adults at the same mean glucose level — clinically minor but worth noting at borderline values.

Insulin Resistance: The Signal Before A1C Rises

A1C and fasting glucose can stay in the normal range for years while insulin resistance is already advancing — the pancreatic beta cells compensate by secreting more insulin until they decompensate. By the time A1C reaches 5.7%, on average ~50% of beta-cell function has already been lost. HOMA-IR (Homeostasis Model Assessment of Insulin Resistance), calculated from fasting insulin and fasting glucose, can flag insulin resistance years before glycemia rises. If your A1C is in the upper-normal range (5.4–5.6%) and you have risk factors (overweight, family history, PCOS, fatty liver, sedentary), discuss adding fasting insulin to your next blood draw with your doctor.

Lifestyle Interventions That Lower HbA1c

The Diabetes Prevention Program (DPP, PMID 11832527) and Finnish DPS (PMID 11333990) demonstrated that a structured lifestyle protocol reduced incident diabetes by ~58% over 3 years in adults with prediabetes — a larger effect than metformin (31% in DPP). The benefit persisted at 10 years (DPPOS, PMID 19878986, 34% reduction). The intervention combined four pillars.

Action Plan by HbA1c Level